Evidence map›Paper›PMID 41767278›Full record

ReviewiScience2026

Anticancer selenopeptides from food sources: synthesis strategies and multitarget mechanisms.

Mingyu Ma, Xiaotong Zhou, Xinyue Qiao, Linling Li, Shuiyuan Cheng, Yingtang Lu, Hua Cheng

Abstract readReview
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingyu MaSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.
Xiaotong ZhouSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.
Xinyue QiaoSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.
Linling LiSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.
Shuiyuan ChengSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.
Yingtang LuSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.
Hua ChengSchool of Modern Industry for Selenium Science and Engineering, Wuhan Polytechnic University, Wuhan 430048, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dual challenges of drug resistance and toxicity in cancer therapy necessitate the development of new drugs with high efficacy and safety. Selenopeptides, which synergistically combine selenium's redox regulation capabilities with the tumor-targeting specificity of peptides, represent a promising frontier in antitumor drug development. Based on the recent literature, this review summarizes the sources and preparation methods of selenium peptides, such as enzymatic hydrolysis and solid/liquid-phase synthesis. Furthermore, it elucidates their multitarget mechanisms of action, including the modulation of the PI3K/Akt signaling pathway, activation of immune cells, inhibition of angiogenesis, and induction of cancer cell apoptosis. Evidence from

Indexed as

biomolecular engineeringbiotechnologymedical biotechnology

Identifiers

PMID41767278
PMCPMC12936831

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.